Skip to main content
Clinical Trials/NCT05622838
NCT05622838
Not yet recruiting
Not Applicable

Maternal alpha1 Antitrypsin as a Marker of Intrauterine Growth Restriction in Pre-eclamptic Women

Assiut University0 sites160 target enrollmentDecember 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
alpha1 Anti-trypsin
Sponsor
Assiut University
Enrollment
160
Primary Endpoint
Assessment of serum alpha-1 anti-trypsin levels during pregnancy and their relationship with intrauterine growth restriction and pre eclampsia.
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

Intrauterine growth restriction (IUGR) is defined as a velocity of fetal growth less than the normal fetus growth potential for a specific neonate as per the race and gender. These neonates face many acute problems during peripartum and after birth .The causes of IUGR may be maternal, placental, fetal or genetic and also due to combination of any of these factors. Knowledge of etiologies of fetal growth restriction (FGR) is essential, so that future care can be targeted at prevention . It is apparent that FGR is primarily caused by placental dysfunction (PIH&PE), insufficiency that lead to reduced fetal growth overall. FGR is associated with lifelong burden of chronic diseases including metabolic, respiratory, cardiovascular and neurological deficits. Pre-eclampsia (PE) is diagnosed by the combined presentation of high blood pressure and proteinuria. New definitions also include maternal organ dysfunction, such as renal, liver, neurological or haematological complications, uteroplacental dysfunction, or FGR . In an attempt to correct fetus reduced supply the placenta release various cytokines and markers as Alpha-1 anti-trypsin (AAT). The Golgi apparatus secretes this cytokine in placental cytotrophoblast and blood vessels. AAT is antinflammatory antiprotease protective molecule. AAT rises during normal pregnancy. The suboptimal rise of AAT in pregnancy are liable for increased obstetrical complications like abortion, preterm labor. AAT levels were found decreased in placenta tissues from women with PE compared that of healthy women. Although AAT deficiency is associated with several pregnancy and placental disorders, little is known regarding AAT levels and PE .

Registry
clinicaltrials.gov
Start Date
December 2022
End Date
January 2025
Last Updated
3 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Maryam Elwany Eldreemy

principal investigator

Assiut University

Eligibility Criteria

Inclusion Criteria

  • Pregnant Pre-eclamptic women with IUGR at 32-36 weeks
  • Pregnant Pre-eclamptic women with healthy fetus at 32-36 weeks
  • Normal pregnant women with healthy fetus

Exclusion Criteria

  • Multiple pregnancy.
  • Congenital fetal anomalies.
  • Pregnant women with personal history of chronic hypertension.
  • Pregnant women with renal failure.
  • Pregnant women with cardiovascular disease.
  • Pregnant women with diabetes mellitus.

Outcomes

Primary Outcomes

Assessment of serum alpha-1 anti-trypsin levels during pregnancy and their relationship with intrauterine growth restriction and pre eclampsia.

Time Frame: expected time of 2 years

The levels of alpha-1 anti-trypsin will be measured in pregnant women and then will be correlated with the occurence of pre-eclampsia and intrauterine growth restriction

Secondary Outcomes

  • Involvement of the results of this study in prediction and prevention of the disease.(expected time of 2 years)

Similar Trials